[go: up one dir, main page]

BR0114917A - Inibidores de pirimidina-2,4,6-triona metaloproteinase - Google Patents

Inibidores de pirimidina-2,4,6-triona metaloproteinase

Info

Publication number
BR0114917A
BR0114917A BR0114917-2A BR0114917A BR0114917A BR 0114917 A BR0114917 A BR 0114917A BR 0114917 A BR0114917 A BR 0114917A BR 0114917 A BR0114917 A BR 0114917A
Authority
BR
Brazil
Prior art keywords
pyrimidine
metalloproteinase inhibitors
trione
trione metalloproteinase
inhibitors
Prior art date
Application number
BR0114917-2A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0114917A publication Critical patent/BR0114917A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dental Preparations (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"INIBIDORES DE PIRIMIDINA-2,4,6-TRIONA METALOPROTEINASE". A presente invenção relaciona-se com os compostos de pirimidina-2,4,6-triona, inibidores da metaloprotease. da fórmula em que X, Y, A, B e R^ 1^ são como definidos no relatório, e com as formulações farmacêuticas e os métodos de tratar a inflamação, o câncer e outros distúrbios.
BR0114917-2A 2000-10-26 2001-10-17 Inibidores de pirimidina-2,4,6-triona metaloproteinase BR0114917A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24331400P 2000-10-26 2000-10-26
PCT/IB2001/001953 WO2002034726A2 (en) 2000-10-26 2001-10-17 Pyrimidine-2,4,6-trione metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
BR0114917A true BR0114917A (pt) 2003-07-01

Family

ID=36950891

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114917-2A BR0114917A (pt) 2000-10-26 2001-10-17 Inibidores de pirimidina-2,4,6-triona metaloproteinase

Country Status (36)

Country Link
US (2) US6706723B2 (pt)
EP (1) EP1332136A2 (pt)
JP (1) JP2004512327A (pt)
KR (1) KR20030061825A (pt)
CN (1) CN1714084A (pt)
AP (1) AP2001002319A0 (pt)
AR (1) AR035362A1 (pt)
AU (1) AU2002210800A1 (pt)
BG (1) BG107651A (pt)
BR (1) BR0114917A (pt)
CA (1) CA2425280A1 (pt)
CR (1) CR6939A (pt)
CZ (1) CZ20031069A3 (pt)
EA (1) EA200300409A1 (pt)
EC (1) ECSP034568A (pt)
EE (1) EE200300195A (pt)
GT (1) GT200100214A (pt)
HN (1) HN2001000243A (pt)
HR (1) HRP20030331A2 (pt)
HU (1) HUP0302337A3 (pt)
IL (1) IL154946A0 (pt)
IS (1) IS6749A (pt)
MA (1) MA26956A1 (pt)
MX (1) MXPA03003734A (pt)
NO (1) NO20031852L (pt)
NZ (1) NZ524774A (pt)
OA (1) OA12528A (pt)
PA (1) PA8531501A1 (pt)
PE (1) PE20020585A1 (pt)
PL (1) PL362919A1 (pt)
SK (1) SK4872003A3 (pt)
SV (1) SV2003000704A (pt)
TN (1) TNSN01150A1 (pt)
UY (1) UY26981A1 (pt)
WO (1) WO2002034726A2 (pt)
ZA (1) ZA200302192B (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60128683T2 (de) * 2000-04-11 2008-01-24 Sankyo Co., Ltd. Stabilisierte pharmazeutische zusammenstellungen die den calziumkanalblocker azelnidipine enthalten
KR20030061825A (ko) * 2000-10-26 2003-07-22 화이자 프로덕츠 인크. 피리미딘-2,4,6-트리온 메탈로프로테이나제 억제제
EP1368327B1 (en) 2001-02-14 2004-10-20 Warner-Lambert Company LLC Benzo thiadiazine matrix metalloproteinase inhibitors
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
DOP2002000332A (es) 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
DOP2002000333A (es) 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
WO2002064571A1 (en) 2001-02-14 2002-08-22 Warner-Lambert Company Llc Pyrimidine matrix metalloproteinase inhibitors
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
JP4164028B2 (ja) 2001-10-12 2008-10-08 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アルキンマトリックスメタロプロテイナーゼ阻害剤
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
WO2003053940A1 (en) 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Barbituric acid derivatives as inhibitors of tnf-$g(a) converting enzyme (tace) and/or matrix metalloproteinases
US7294624B2 (en) * 2001-12-20 2007-11-13 Bristol Myers Squibb Company Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
WO2003090751A1 (en) * 2002-04-26 2003-11-06 Pfizer Products Inc. Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
EP1501834B1 (en) 2002-04-26 2005-09-07 Pfizer Products Inc. Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
AU2003216660A1 (en) * 2002-04-26 2003-11-10 Pfizer Products Inc. N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
NI200300045A (es) 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
WO2004014892A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Monocyclic derivatives as matrix metalloproteinase inhibitors
AU2003250466A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
AU2003249531A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
JP2006500351A (ja) 2002-08-13 2006-01-05 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテアーゼ−１３阻害剤としてのピリミジン−２，４−ジオン誘導体
WO2004014375A2 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
WO2004014908A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
JP2005539020A (ja) 2002-08-13 2005-12-22 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー マトリクスメタロプロテイナーゼ阻害物質としてのクロモン誘導体
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
WO2004014923A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
WO2004014909A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
GB0223249D0 (en) * 2002-10-08 2002-11-13 Amersham Plc Improved imaging agents
WO2004084903A1 (en) * 2003-03-27 2004-10-07 F. Hoffmann-La Roche Ag Use of a trioxopyrimidine for the treatment and prevention of ocular pathologic angiogenesis
WO2004084902A1 (en) * 2003-03-28 2004-10-07 F. Hoffmann-La Roche Ag Use of a trioxopyrimidine for the treatment of chronic wounds
ES2537514T3 (es) 2003-04-04 2015-06-09 Incyte Corporation Composiciones, métodos y kits relacionados con la escisión de HER-2
DE602005008418D1 (de) * 2004-04-01 2008-09-04 Hoffmann La Roche Verwendung von trioxopyrimidin zur behandlung und prävention von entzündlichen erkrankungen der bronchien
ES2282062T1 (es) 2004-06-04 2007-10-16 Teva Pharmaceutical Industries Ltd. Composicion farmaceutica que contiene irbesartan.
TW200806648A (en) * 2005-11-29 2008-02-01 Sankyo Co Acid addition salts of dihydropyridine derivatives
TW200736245A (en) * 2005-11-29 2007-10-01 Sankyo Co Acid addition salts of optically active dihydropyridine derivatives
EP3144299A1 (en) * 2009-05-05 2017-03-22 Cambria Pharmaceuticals, Inc. Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis
RU2400233C1 (ru) 2009-07-07 2010-09-27 Общество с ограниченной ответственностью "Вирфарм" Способ лечения заболеваний печени различного генеза
KR101301533B1 (ko) * 2010-02-09 2013-09-04 한미사이언스 주식회사 암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체
US8551982B2 (en) 2011-03-14 2013-10-08 Boehringer Ingelheim International Gmbh Benzodioxane inhibitors of leukotriene production
EP2734516B1 (en) 2011-07-19 2015-06-17 Boehringer Ingelheim International GmbH Arylpyrazole ethers as inhibitors of leukotriene a4 hydrolase
AU2013229560A1 (en) 2012-03-06 2014-08-28 Boehringer Ingelheim International Gmbh Benzodioxanes in combination with other actives for inhibiting leukotriene production
EP2822942B1 (en) 2012-03-06 2017-05-10 Boehringer Ingelheim International GmbH Benzodioxanes for inhibiting leukotriene production
JP6256467B2 (ja) 2012-07-17 2018-01-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成を阻害するピラゾール誘導体
RU2644250C2 (ru) * 2012-09-14 2018-02-08 Элизабет ЛЕВИНА Лекарственное средство с активностью против грамположительных бактерий, микобактерий и грибов
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
WO2015009609A1 (en) 2013-07-15 2015-01-22 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
EP3022194B1 (en) 2013-07-15 2017-05-17 Boehringer Ingelheim International GmbH Inhibitors of leukotriene production
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
IL315313A (en) * 2018-08-24 2024-10-01 Xeniopro GmbH Aromatic molecules for use in the treatment of pathological conditions
US11957671B2 (en) 2021-11-01 2024-04-16 Alkahest, Inc. Benzodioxane modulators of leukotriene A4 hydrolase (LTA4H) for prevention and treatment of aging-associated diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19548624A1 (de) 1995-12-23 1997-06-26 Boehringer Mannheim Gmbh Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
JP2002504916A (ja) * 1997-06-21 2002-02-12 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗転移及び抗腫瘍活性を有するバルビツール酸誘導体
DE19726427A1 (de) 1997-06-23 1998-12-24 Boehringer Mannheim Gmbh Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6265578B1 (en) 1999-02-12 2001-07-24 Hoffmann-La Roche Inc. Pyrimidine-2,4,6-triones
PA8498701A1 (es) * 1999-08-12 2002-08-26 Pfizer Prod Inc Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
KR20030061825A (ko) * 2000-10-26 2003-07-22 화이자 프로덕츠 인크. 피리미딘-2,4,6-트리온 메탈로프로테이나제 억제제

Also Published As

Publication number Publication date
GT200100214A (es) 2002-07-03
US20050107414A1 (en) 2005-05-19
SV2003000704A (es) 2003-01-13
PE20020585A1 (es) 2002-07-06
MA26956A1 (fr) 2004-12-20
WO2002034726A3 (en) 2002-10-17
CN1714084A (zh) 2005-12-28
HN2001000243A (es) 2002-11-07
AR035362A1 (es) 2004-05-12
CA2425280A1 (en) 2002-05-02
HUP0302337A2 (hu) 2003-10-28
AP2001002319A0 (en) 2001-12-31
OA12528A (en) 2006-06-02
PL362919A1 (en) 2004-11-02
JP2004512327A (ja) 2004-04-22
IL154946A0 (en) 2003-10-31
TNSN01150A1 (fr) 2005-11-10
MXPA03003734A (es) 2003-07-28
NZ524774A (en) 2004-09-24
WO2002034726A9 (en) 2003-03-06
ZA200302192B (en) 2004-05-05
HRP20030331A2 (en) 2003-06-30
KR20030061825A (ko) 2003-07-22
PA8531501A1 (es) 2003-06-30
SK4872003A3 (en) 2004-08-03
US6706723B2 (en) 2004-03-16
EE200300195A (et) 2003-10-15
CR6939A (es) 2003-11-25
HUP0302337A3 (en) 2004-01-28
WO2002034726A2 (en) 2002-05-02
NO20031852D0 (no) 2003-04-24
UY26981A1 (es) 2002-06-20
US20020132822A1 (en) 2002-09-19
NO20031852L (no) 2003-06-23
BG107651A (bg) 2003-12-31
ECSP034568A (es) 2003-06-25
EA200300409A1 (ru) 2003-08-28
IS6749A (is) 2003-03-17
AU2002210800A1 (en) 2002-05-06
EP1332136A2 (en) 2003-08-06
CZ20031069A3 (cs) 2004-05-12

Similar Documents

Publication Publication Date Title
BR0114917A (pt) Inibidores de pirimidina-2,4,6-triona metaloproteinase
BR0308787A (pt) Inibidores de metaloproteinase de n-substituìdos-heteroarilóxi-aril-espiro-pirimidina- 2,4,6-triona
BR0309556A (pt) Inibidores de metaloproteinase pirimidina-2,4,6-triona
UY26285A1 (es) Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
BR0114913A (pt) Inibidores de metaloproteinase de espiro-pirimidina-2,4,6-triona
BR0010342A (pt) Composto, droga, e, uso de composto da fórmula i ou ii
BR0314393A (pt) Piperazinas heterocìclicas substituìdas para o tratamento de esquizofrenia
BR0111451A (pt) Inibidores de serina protease
BR0309386A (pt) Inibidores de metaloproteinases de triaril-óxi-arilóxi-pirimidina-2,4,6-triona
PT1390371E (pt) Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
AR021643A1 (es) Combinacion de cerivastatina y fibratos.
BR0111915A (pt) 5-aminoalquilpirazolo[4,3-d]pirimidinas
BR0108500A (pt) Arilpiperazinas e arilpiperidinas e seu uso como agentes inibidores de metaloproteinase
SE9802209D0 (sv) Novel compounds
ATE420636T1 (de) Hemmer der protonenabhängigen kationenkanäle und deren verwendung in der behandlung von ischemiebedingten erkrankungen
DK1244643T3 (da) Tryptaseinhibitorer
AP2002002417A0 (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors.
PT1244614E (pt) Inibidores de triptase
BR0000901A (pt) Derivados 4-fenil-4-heteroarilpiperidina
SV2002000626A (es) Amidas de acido fenilciclohexanocarboxilico sustituido y su uso ref. lea 34750-sv
BR0112092A (pt) 2-aminoalquiltieno[2,3-d]pirimidinas
ATE348803T1 (de) Tryptase-inhibitoren
PT1358182E (pt) Derivados de diazocinas e sua utilizacao como inibidores de triptase
BRPI0415716A (pt) derivados do ácido acremÈnico

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2021 DE 29/09/2009.